EG24774A - Quinoline derivatives as phosphodiesterase inhibitors. - Google Patents
Quinoline derivatives as phosphodiesterase inhibitors.Info
- Publication number
- EG24774A EG24774A EGNA2005000730A EG24774A EG 24774 A EG24774 A EG 24774A EG NA2005000730 A EGNA2005000730 A EG NA2005000730A EG 24774 A EG24774 A EG 24774A
- Authority
- EG
- Egypt
- Prior art keywords
- phosphodiesterase inhibitors
- quinoline derivatives
- quinoline
- derivatives
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0311688A GB0311688D0 (en) | 2003-05-21 | 2003-05-21 | Compounds |
| GB0326187A GB0326187D0 (en) | 2003-11-10 | 2003-11-10 | Compounds |
| PCT/EP2004/005494 WO2004103998A1 (en) | 2003-05-21 | 2004-05-19 | Quinoline derivatives as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG24774A true EG24774A (en) | 2010-08-19 |
Family
ID=33477765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EGNA2005000730 EG24774A (en) | 2003-05-21 | 2005-11-15 | Quinoline derivatives as phosphodiesterase inhibitors. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7566786B2 (pt) |
| EP (2) | EP1633748B1 (pt) |
| JP (1) | JP4625460B2 (pt) |
| KR (1) | KR101144548B1 (pt) |
| CN (1) | CN1823063B (pt) |
| AR (1) | AR044401A1 (pt) |
| AT (2) | ATE388148T1 (pt) |
| AU (1) | AU2004240759B2 (pt) |
| BR (1) | BRPI0410477A (pt) |
| CA (1) | CA2526228C (pt) |
| CO (1) | CO5700780A2 (pt) |
| CY (2) | CY1108094T1 (pt) |
| DE (1) | DE602004012260T2 (pt) |
| DK (2) | DK1944305T3 (pt) |
| EG (1) | EG24774A (pt) |
| ES (2) | ES2374850T3 (pt) |
| HK (2) | HK1092458A1 (pt) |
| HR (2) | HRP20080236T3 (pt) |
| IL (1) | IL171726A (pt) |
| IS (1) | IS2581B (pt) |
| MA (1) | MA27808A1 (pt) |
| MX (1) | MXPA05012466A (pt) |
| NO (1) | NO330754B1 (pt) |
| NZ (1) | NZ543554A (pt) |
| PL (2) | PL1944305T3 (pt) |
| PT (2) | PT1944305E (pt) |
| RU (1) | RU2335493C2 (pt) |
| SI (2) | SI1944305T1 (pt) |
| TW (1) | TWI328009B (pt) |
| WO (1) | WO2004103998A1 (pt) |
| ZA (1) | ZA200509319B (pt) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| GB0425572D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | 1,7-Naphthyridines |
| ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
| GB0503955D0 (en) * | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| GB0505621D0 (en) * | 2005-03-18 | 2005-04-27 | Glaxo Group Ltd | Novel compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| CA2621406A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
| GB0521563D0 (en) | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| EP1989188B1 (en) * | 2006-02-28 | 2015-07-22 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as pde4 inhibitors |
| MX2008011257A (es) * | 2006-03-08 | 2008-09-25 | Amgen Inc | Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10. |
| GB0605462D0 (en) * | 2006-03-17 | 2006-04-26 | Glaxo Group Ltd | Novel compounds |
| US7943651B2 (en) | 2006-04-20 | 2011-05-17 | Glaxo Group Limited | Compounds |
| JP4528901B2 (ja) * | 2006-04-28 | 2010-08-25 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するアミン誘導体 |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| AR061571A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US8431578B2 (en) | 2008-01-11 | 2013-04-30 | Novartis Ag | Organic compounds |
| BRPI0912267A2 (pt) | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
| JP5502858B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体 |
| US8729097B2 (en) | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
| JP2012513464A (ja) * | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| JP2012515148A (ja) | 2009-01-13 | 2012-07-05 | グラクソ グループ リミテッド | Ｓｙｋキナーゼ阻害剤としてのピリミジンカルボキサミド誘導体 |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| US20120058984A1 (en) | 2009-03-17 | 2012-03-08 | Catherine Mary Alder | Pyrimidine derivatives used as itk inhibitors |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| EA201171144A1 (ru) | 2009-03-19 | 2012-04-30 | Мерк Шарп Энд Домэ Корп. | ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| EP2411516A1 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012524754A (ja) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| KR101679642B1 (ko) | 2009-04-30 | 2016-11-25 | 글락소 그룹 리미티드 | Ｐｉ3키나아제 억제제로서 옥사졸 치환된 인다졸 |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
| US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| AU2011253203A1 (en) | 2010-05-10 | 2012-11-22 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| WO2011143106A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bi - functional pyrazolopyridine compounds |
| EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| PT2614058E (pt) | 2010-09-08 | 2015-10-27 | Glaxosmithkline Ip Dev Ltd | Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| JP2013544794A (ja) | 2010-10-21 | 2013-12-19 | グラクソ グループ リミテッド | アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物 |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US20130225524A1 (en) * | 2010-11-05 | 2013-08-29 | Deping Chai | Chemical Compounds |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| AU2012225735B2 (en) * | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体 |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| CN104010504B (zh) * | 2011-11-03 | 2016-04-06 | 默沙东公司 | 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| KR20210007046A (ko) | 2013-02-01 | 2021-01-19 | 웰스태트 테러퓨틱스 코포레이션 | 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물 |
| ES2654100T3 (es) | 2013-02-21 | 2018-02-12 | Glaxosmithkline Intellectual Property Development Limited | Quinazolinas como inhibidores de quinasa |
| AU2014336251A1 (en) | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
| US20160256466A1 (en) | 2013-10-17 | 2016-09-08 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| CA2948441A1 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| JP6449482B2 (ja) * | 2015-03-24 | 2019-01-09 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| CA3047579A1 (en) * | 2016-12-22 | 2018-06-28 | Mavupharma, Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
| WO2024153112A1 (zh) * | 2023-01-17 | 2024-07-25 | 瑞石生物医药有限公司 | Pde4抑制剂、其制备方法及其在医药上的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE46886B1 (en) | 1977-05-17 | 1983-10-19 | Allen & Hanburys Ltd | Aminoalkyl-benzene derivatives |
| EP0048005A3 (de) * | 1980-09-17 | 1983-01-19 | ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH | Vorrichtung zum Stapeln von Geschirr |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| EP0480052B1 (en) | 1990-03-28 | 1998-01-14 | Otsuka Pharmaceutical Co., Ltd. | Quinoline derivative, antiulcer drug containing the same, and production of said derivative |
| US5214191A (en) | 1990-05-22 | 1993-05-25 | Cortech, Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP0752853B1 (en) | 1993-03-10 | 2005-09-21 | Smithkline Beecham Corporation | Human brain phosphodiesterase |
| FR2705346B1 (fr) | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
| DK122693D0 (da) | 1993-10-29 | 1993-10-29 | Hempels Skibsfarve Fab J C | Marin struktur |
| ATE191470T1 (de) | 1994-06-15 | 2000-04-15 | Wellcome Found | Enzymhemmer |
| JP2000510866A (ja) * | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド |
| WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| KR100567649B1 (ko) | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| GB9712761D0 (en) * | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| NZ505362A (en) | 1997-12-22 | 2004-12-24 | Upjohn Co | 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| EP1950201A1 (en) | 1998-09-29 | 2008-07-30 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| JP4548642B2 (ja) | 1998-09-29 | 2010-09-22 | アメリカン・サイアナミド・カンパニー | プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン |
| MY121142A (en) | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
| BR0008731A (pt) | 1999-03-15 | 2002-09-24 | Abbott Lab | Macrolìdeos 6-0-substituìdos, tendo atividade antibacteriana |
| GB0008485D0 (en) * | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| ATE348826T1 (de) | 2000-07-26 | 2007-01-15 | Smithkline Beecham Plc | Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung |
| US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| PL362711A1 (en) | 2000-09-29 | 2004-11-02 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| AU2001295791A1 (en) | 2000-11-02 | 2002-05-15 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| SE0101675D0 (sv) * | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| JP2003005355A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はｘ線用ネガ型レジスト組成物 |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| CA2464214C (en) | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| CA2468159A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| US7176314B2 (en) | 2001-12-05 | 2007-02-13 | Amgen, Inc. | Inflammation modulators |
| US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| EP1513828A1 (en) | 2002-06-20 | 2005-03-16 | Biovitrum AB | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
| WO2004067513A1 (en) | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonists for alpha-2 adrenoceptors |
| WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
-
2004
- 2004-05-14 TW TW093113762A patent/TWI328009B/zh not_active IP Right Cessation
- 2004-05-19 BR BRPI0410477-3A patent/BRPI0410477A/pt not_active IP Right Cessation
- 2004-05-19 DK DK08152215.3T patent/DK1944305T3/da active
- 2004-05-19 AR ARP040101734A patent/AR044401A1/es unknown
- 2004-05-19 RU RU2005135016/04A patent/RU2335493C2/ru not_active IP Right Cessation
- 2004-05-19 DE DE602004012260T patent/DE602004012260T2/de not_active Expired - Lifetime
- 2004-05-19 WO PCT/EP2004/005494 patent/WO2004103998A1/en active IP Right Grant
- 2004-05-19 DK DK04733799T patent/DK1633748T3/da active
- 2004-05-19 PT PT08152215T patent/PT1944305E/pt unknown
- 2004-05-19 KR KR1020057022135A patent/KR101144548B1/ko not_active IP Right Cessation
- 2004-05-19 JP JP2006529889A patent/JP4625460B2/ja not_active Expired - Fee Related
- 2004-05-19 CA CA2526228A patent/CA2526228C/en not_active Expired - Fee Related
- 2004-05-19 AT AT04733799T patent/ATE388148T1/de active
- 2004-05-19 AT AT08152215T patent/ATE529421T1/de active
- 2004-05-19 PL PL08152215T patent/PL1944305T3/pl unknown
- 2004-05-19 CN CN2004800206511A patent/CN1823063B/zh not_active Expired - Fee Related
- 2004-05-19 SI SI200431802T patent/SI1944305T1/sl unknown
- 2004-05-19 MX MXPA05012466A patent/MXPA05012466A/es active IP Right Grant
- 2004-05-19 PT PT04733799T patent/PT1633748E/pt unknown
- 2004-05-19 PL PL04733799T patent/PL1633748T3/pl unknown
- 2004-05-19 AU AU2004240759A patent/AU2004240759B2/en not_active Ceased
- 2004-05-19 SI SI200430691T patent/SI1633748T1/sl unknown
- 2004-05-19 ES ES08152215T patent/ES2374850T3/es not_active Expired - Lifetime
- 2004-05-19 US US10/557,079 patent/US7566786B2/en not_active Expired - Fee Related
- 2004-05-19 NZ NZ543554A patent/NZ543554A/en not_active IP Right Cessation
- 2004-05-19 EP EP04733799A patent/EP1633748B1/en not_active Expired - Lifetime
- 2004-05-19 EP EP08152215A patent/EP1944305B1/en not_active Expired - Lifetime
- 2004-05-19 ES ES04733799T patent/ES2301993T3/es not_active Expired - Lifetime
-
2005
- 2005-10-31 IS IS8110A patent/IS2581B/is unknown
- 2005-11-02 IL IL171726A patent/IL171726A/en not_active IP Right Cessation
- 2005-11-15 EG EGNA2005000730 patent/EG24774A/xx active
- 2005-11-16 NO NO20055421A patent/NO330754B1/no not_active IP Right Cessation
- 2005-11-16 CO CO05116284A patent/CO5700780A2/es active IP Right Grant
- 2005-11-17 ZA ZA200509319A patent/ZA200509319B/xx unknown
- 2005-11-21 MA MA28611A patent/MA27808A1/fr unknown
-
2006
- 2006-02-08 US US11/349,677 patent/US7572915B2/en not_active Expired - Fee Related
- 2006-02-08 US US11/349,701 patent/US20070049570A1/en not_active Abandoned
- 2006-09-07 HK HK06109975A patent/HK1092458A1/xx not_active IP Right Cessation
-
2008
- 2008-05-23 CY CY20081100534T patent/CY1108094T1/el unknown
- 2008-05-29 HR HR20080236T patent/HRP20080236T3/xx unknown
- 2008-08-21 HK HK08109372.1A patent/HK1118274A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 US US12/474,324 patent/US20090312325A1/en not_active Abandoned
-
2011
- 2011-12-20 HR HR20110957T patent/HRP20110957T1/hr unknown
-
2012
- 2012-01-11 CY CY20121100032T patent/CY1112232T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG24774A (en) | Quinoline derivatives as phosphodiesterase inhibitors. | |
| AP2321A (en) | Quinoline derivatives for use as mycobactrial inhibitor. | |
| AP2005003353A0 (en) | Diazepinoindole derivatives as kinase inhibitors. | |
| IL172132A0 (en) | Thienopyridone derivatives as kinase inhibitors | |
| ZA200603657B (en) | Novel quinoline derivatives | |
| HK1093503A1 (en) | Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors | |
| IL173381A0 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
| IL165515A0 (en) | Bisindolyl-maleimid derivatives as kinase inhibitors | |
| AP2006003553A0 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors. | |
| HK1054034A1 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors. | |
| IL172375A0 (en) | Chinazoline derivatives as aurora kinase inhibitors | |
| AP2006003552A0 (en) | N3 - substituted imidazopyridine C-kit inhibitors. | |
| IL172793A0 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| EP1570847A4 (en) | PHOSPHODIESTERASE 10A HEMMER | |
| GB0317484D0 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| GB0317482D0 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| EG24415A (en) | Quinoline derivatives | |
| GB0317509D0 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| GB0317472D0 (en) | Nicotinamide derivatives useful as PDE4 inhibitors |